STOCK TITAN

Niagen Bioscience (NAGE) Stock Price, News & Analysis

NAGE NASDAQ

Ticker history: CDXC became NAGE (Niagen Bioscience, Inc.) on . Earlier news and filings retain their original names and dates. View CDXC history.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
19 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
-16.5% close of November 5, 2026
1-year change
-70.5% closing prices, November 13, 2025 to November 13, 2026
1-month change
-20% closing prices, October 13, 2026 to November 13, 2026

Company Description

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is a bioscience company in the healthcare sector focused on biotechnology, NAD+ (nicotinamide adenine dinucleotide) science, and healthy-aging research. The company describes itself as the global authority and a trusted pioneer in NAD+ discoveries, dedicated to advancing healthspan through precision science and NAD+-boosting solutions built around its patented ingredient Niagen® (nicotinamide riboside, or NR).

Core focus on NAD+ biology and healthy aging

According to multiple company disclosures and press releases, Niagen Bioscience concentrates on understanding and applying NAD+ biology. NAD+ is described as a vital coenzyme found in every cell of the human body, essential for cellular energy production, DNA repair, metabolism, and overall cellular health. The company highlights that NAD+ levels decline with age and exposure to everyday lifestyle stressors, and that this depletion is a key contributor to age-related changes in health and vitality. Niagen Bioscience positions its work as addressing this decline through NAD+ precursors, particularly nicotinamide riboside.

Niagen® and NAD+ precursor platform

At the center of Niagen Bioscience’s business is Niagen®, its patented form of nicotinamide riboside (NR). Company materials repeatedly describe Niagen as the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen is commercialized in both food-grade and pharmaceutical-grade forms and is protected by a robust patent portfolio that covers NR and other NAD+ precursors. The company reports that its intellectual property estate includes dozens of issued and pending patents worldwide, with a large concentration focused specifically on NR and its derivatives.

Niagen Bioscience has also disclosed that it acquired a comprehensive portfolio of existing patents covering NR and its salt forms from Queen’s University Belfast, consolidating ownership of core composition-of-matter and related patents underpinning NR production, composition, and commercial use. These patents include rights to multiple NR salt forms and methods of making NR and other NAD+ precursors across multiple jurisdictions.

Consumer products: Tru Niagen® and Tru Niagen® Beauty

Niagen Bioscience delivers Niagen as the principal dietary ingredient in its consumer supplement line Tru Niagen®. Company communications state that Tru Niagen is the number one NAD+ boosting oral supplement in the United States, based on revenue data from a large U.S. e-commerce marketplace over a defined historical period. Tru Niagen is positioned as a science-backed nutritional supplement for cellular health and healthy aging, available through the company’s direct-to-consumer website and through global retail and distribution partners.

The company has also launched Tru Niagen® Beauty, described as the first NAD+ skincare supplement in the U.S. featuring Niagen. Tru Niagen Beauty is presented as a cellular-first beauty product designed to support skin elasticity and the appearance of hair, skin, and nails. It combines Niagen with a blend of clinically studied ingredients such as astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E, with the stated goal of nourishing beauty from within while complementing core Tru Niagen products.

Clinical-grade offerings: Niagen Plus™ IV and injections

Beyond consumer supplements, Niagen Bioscience develops and commercializes pharmaceutical-grade Niagen® under the Niagen Plus™ brand. These offerings include intravenous (IV) and injectable Niagen products that are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and made available exclusively at clinics with a prescription. The company reports that Niagen IV and injections are offered at hundreds of clinics nationwide, including numerous iCRYO wellness centers, and are intended for individuals seeking NAD+-boosting therapies to support cellular health, recovery, performance, and healthy aging.

Company communications describe Niagen IV as a clinically validated intravenous solution for supporting NAD+ levels, and reference a pilot clinical study in which Niagen IV outperformed NAD+ IV on measures such as tolerability, infusion time, and increases in whole blood NAD+ levels. Niagen Bioscience contrasts Niagen with direct NAD+ supplementation, noting that NAD+ itself is not considered bioavailable in the same way and that oral or intravenous NAD+ has not been well studied in humans.

Research, clinical evidence, and scientific collaborations

Niagen Bioscience emphasizes its scientific orientation and research infrastructure. The company states that Niagen is supported by more than 40 peer-reviewed human clinical studies, over 500 published scientific papers, and more than 50 patents worldwide. It highlights collaborations with independent investigators from universities and research institutions around the globe, and notes that its team includes world-renowned scientists and advisors in fields such as metabolism, brain health, and aging.

The company has reported results from a randomized, double-blind, placebo-controlled clinical trial using Niagen in individuals with long COVID (post-acute sequelae of SARS-CoV-2 infection). According to the published summary, Niagen supplementation in this study significantly increased NAD+ levels and showed within-group improvements from baseline in measures such as fatigue, sleep quality, depression, and executive functioning, while between-group differences versus placebo were not statistically significant. Niagen Bioscience presents this as evidence that restoring NAD+ is a measurable biological response and a potential avenue for further research in conditions of metabolic and cellular stress.

Digital and educational platforms: AboutNAD®

In addition to products, Niagen Bioscience operates AboutNAD®, described as a centralized educational resource and research database focused on NAD+ biology. The platform curates peer-reviewed literature, scientific explainers, and expert perspectives on NAD+ and NAD+ precursors, with a particular emphasis on nicotinamide riboside. It offers categorized research, advanced search tools, and educational content aimed at consumers, clinicians, and researchers who want to understand the published science behind NAD+ and healthy aging.

Business activities and revenue drivers

Company filings and press releases indicate that Niagen Bioscience generates revenue through several related activities:

  • Sales of Tru Niagen-branded consumer dietary supplements through direct-to-consumer channels and retail and distribution partners.
  • Supply of food-grade Niagen as a raw material ingredient to manufacturers of consumer products.
  • Commercialization of pharmaceutical-grade Niagen Plus IV and injectable products through U.S. FDA-registered 503B outsourcing facilities and clinic networks.
  • Sales of natural product fine chemicals (phytochemicals) and related research and development services.

In investor communications, the company has also discussed e-commerce momentum, new business-to-business partnerships, and expansion of clinical distribution networks as contributors to its growth outlook.

Intellectual property and supply agreements

Niagen Bioscience’s strategy places significant emphasis on intellectual property protection around NAD+ precursors. The company’s patent portfolio covers NR, NR salt forms, and other NAD+ precursors, including composition-of-matter patents and methods of making these molecules. Through an assignment agreement with Queen’s University Belfast, Niagen Bioscience has become the sole owner of key NR patents that were previously jointly owned or licensed, and it has obtained a release from prior royalty and payment obligations under earlier agreements.

The company has also entered into a supply agreement under which a third-party manufacturer exclusively supplies nicotinamide-beta-riboside chloride (NRCL) to Niagen Bioscience, subject to defined specifications and minimum purchase commitments. The supplier is restricted from selling NRCL to other parties and must notify Niagen Bioscience of any new business inquiries relating to NRCL. The agreement includes provisions for potential future licensing of manufacturing patents under certain conditions.

Capital markets activity and shareholder programs

Niagen Bioscience is listed on NASDAQ under the ticker symbol NAGE. The company has disclosed a share repurchase program authorizing the repurchase of up to a specified dollar amount of its common stock over a multi-year period, with repurchases to be made at management’s discretion in accordance with applicable securities laws. The authorization may be modified, suspended, or terminated by the board of directors and does not obligate the company to repurchase a particular number of shares.

At its annual meeting, the company’s stockholders have approved amendments to its equity incentive plan to increase the number of shares available for issuance, as well as an employee stock purchase plan that allows eligible employees to acquire shares through payroll deductions at a discount to market price, subject to plan limits and terms.

Positioning within biotechnology and healthy-aging markets

Within the broader biotechnology and healthy-aging landscape, Niagen Bioscience presents itself as a company focused on translating cellular and metabolic research into practical NAD+-boosting products. Its activities span consumer health supplements, clinical-grade IV and injectable therapies, ingredient supply, and educational initiatives. The company’s emphasis on peer-reviewed science, clinical trials, and patent protection is central to how it describes its differentiation in the NAD+ category.

Stock Performance

$2.07
+0.24%
+0.00
Pre-marketLast updated: November 16, 2026 at 08:24
-70.5%
Performance 1 year
$163.9M

Niagen Bioscience (NAGE) closed at $2.07 on November 13, 2026. Over the past 12 months, the price has lost 70.5%.

See what a $1,000 investment in NAGE would be worth today

Average down calculator for NAGE

NAGE Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Niagen Bioscience has 10 recent news articles, with the latest published today. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include conferences, earnings, earnings date. View all NAGE news →

Financial Highlights

Niagen Bioscience generated $129.4M in revenue in FY2025, retaining a 64.3% gross margin, operating income reached $16.3M (12.6% operating margin), and net income was $17.4M, reflecting a 13.4% net profit margin. Diluted earnings per share stood at $0.20. The company generated $13.5M in operating cash flow. The current ratio was 4.86, measuring current assets divided by current liabilities.

$129.4M
Revenue (FY2025)
$17.4M
Net Income (FY2025)
$13.5M
Operating Cash Flow

Upcoming Events

NOV
19
November 19, 2026 - November 19, 2026 Marketing

Southwest IDEAS presentation

Company presentation at Southwest IDEAS in Irving, TX on Nov 19 from 4:00–4:35 p.m. CT; management will hold one-on-one meetings.
DEC
09
December 9, 2026 - December 10, 2026 Marketing

Longevity Summit Presentation

Presentation at Buck Institute (Novato, CA) Dec 9–10, 2026 by Abhijit Kale on Niagen Research Program; no webcast noted.
DEC
09
December 9, 2026 - December 12, 2026 Marketing

ROTH Deer Valley meetings

CEO Rob Fried to hold one-on-one investor meetings at the ROTH Deer Valley conference in Park City, UT, Dec 9–12, 2026.
DEC
10
December 10, 2026 Marketing

StoneX one-on-one meetings

CFO Ozan Pamir to conduct one-on-one investor meetings at the StoneX Discovery Conference in New York on Dec 10, 2026.
OCT
31
October 31, 2027 Financial

Share repurchase program expiry

Buyback authorization $20M; program expires 2027-10-31; $2.6M repurchased to 2026-03-17
YEAR
2044
2044 Corporate

Patent protection expiry

U.S. Patent No. 12,558,367 protection ends; covers IV/injectable nicotinamide riboside (Niagen).

Niagen Bioscience has 6 upcoming scheduled events. The next event, "Southwest IDEAS presentation", is scheduled for November 19, 2026 (in 3 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the NAGE stock price.

Short Interest History

Last 12 Months

Short interest in Niagen Bioscience (NAGE) currently stands at 4.3 million shares, up 4.2% from the previous reporting period, representing 7.8% of the float. Since November 2025, short interest has decreased by 21.2%.

Days to Cover History

Last 12 Months

Days to cover for Niagen Bioscience (NAGE) currently stands at 8.9 days, up 43.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 26.7%. Across the settlements charted above, it has ranged from 2.2 to 11.3 days.

NAGE Company Profile & Sector Positioning

Niagen Bioscience (NAGE) operates in the Packaged Foods industry within the broader Consumer Defensive sector and is listed on the NASDAQ.

Investors comparing NAGE often look at related companies in the same sector, including Nature's Sunshine Products Inc. (NATR), BRC Inc. (BRCC), USANA Health Sciences Inc (USNA), Oatly Group AB (OTLY), and Beyond Meat, Inc. (BYND). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate NAGE's relative position within its industry.

Frequently Asked Questions

The current stock price of Niagen Bioscience (NAGE) is $2.07 in pre-market trading as of November 16, 2026.

The market cap of Niagen Bioscience (NAGE) is approximately $163.9M. Learn more about what market capitalization means .

The FY2025 revenue of Niagen Bioscience (NAGE) is $129.4M, from its most recent completed fiscal year.

The FY2025 net income of Niagen Bioscience (NAGE) is $17.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Niagen Bioscience (NAGE) is $0.20 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Niagen Bioscience (NAGE) is $13.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Niagen Bioscience (NAGE) is 13.4% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Niagen Bioscience (NAGE) is 12.6% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Niagen Bioscience (NAGE) is 64.3% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Niagen Bioscience (NAGE), current assets divided by current liabilities, was 4.86 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Niagen Bioscience (NAGE) is $83.2M for FY2025, its most recent completed fiscal year.

The operating income of Niagen Bioscience (NAGE) is $16.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

Niagen Bioscience, Inc. is a bioscience company in the healthcare sector that focuses on NAD+ science and healthy-aging research. It develops and commercializes NAD+-boosting products centered on its patented nicotinamide riboside ingredient Niagen®, including Tru Niagen consumer supplements and Niagen Plus IV and injectable formulations.

NAD+ (nicotinamide adenine dinucleotide) is described by the company as a vital coenzyme found in every cell, essential for energy production, DNA repair, and cellular metabolism. Niagen Bioscience’s research and products are built around restoring or supporting NAD+ levels using precursors such as nicotinamide riboside, with the goal of addressing age-related NAD+ decline and its impact on health and vitality.

Niagen is Niagen Bioscience’s patented form of nicotinamide riboside (NR), which the company describes as the most efficient, well-researched, high-quality, and legal NAD+ booster available. It is the key active ingredient in Tru Niagen supplements and Niagen Plus IV and injectable products and is protected by a broad patent portfolio that underpins the company’s NAD+ business.

Niagen Bioscience markets Tru Niagen, a dietary supplement that uses Niagen as its principal ingredient and is positioned for cellular health and healthy aging. The company states that Tru Niagen is the number one NAD+ boosting oral supplement in the United States over a defined historical period, and it sells the product through its own website and through retailer and distributor partnerships.

Niagen Plus is the company’s pharmaceutical-grade Niagen platform, which includes intravenous (IV) and injectable products. These formulations are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available only at clinics with a prescription. They are intended for individuals seeking NAD+-boosting therapies delivered in a clinical environment.

Tru Niagen Beauty is a supplement introduced by Niagen Bioscience that combines Niagen with clinically studied ingredients such as astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E. It is designed to support skin elasticity and the appearance of hair, skin, and nails while complementing daily Tru Niagen regimens.

The company reports a robust patent estate with numerous issued and pending patents worldwide covering Niagen, its salt forms, and other NAD+ precursors. Through an assignment agreement with Queen’s University Belfast, Niagen Bioscience became the sole owner of core patents related to NR production, composition, and use, including composition-of-matter patents for multiple NR salt forms.

Niagen Bioscience states that Niagen is supported by more than 40 peer-reviewed human clinical studies and over 500 published scientific papers related to NAD+ science. The company has highlighted a randomized controlled trial in individuals with long COVID, where Niagen supplementation increased NAD+ levels and showed within-group improvements in fatigue, sleep quality, depression, and executive functioning compared to baseline.

AboutNAD is a digital platform created by Niagen Bioscience that serves as an educational resource and research database on NAD+ biology. It offers categorized research, expert commentary, and accessible explainers focused on NAD+ and nicotinamide riboside, aimed at consumers, healthcare professionals, and scientists who want to explore the published science behind NAD+ and healthy aging.

Niagen Bioscience’s common stock trades on NASDAQ under the symbol NAGE. The company has adopted and amended equity incentive plans and an employee stock purchase plan that allow eligible employees and officers to acquire shares, subject to plan terms. It has also authorized a share repurchase program permitting the company to buy back a specified amount of its common stock over a defined period, at management’s discretion.